{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:27Z","timestamp":1792181727013,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"21","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.vaccine.2005.08.034","type":"journal-article","created":{"date-parts":[[2005,8,23]],"date-time":"2005-08-23T18:13:25Z","timestamp":1124820805000},"page":"4657-4666","source":"Crossref","is-referenced-by-count":121,"title":["Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus"],"prefix":"10.1016","volume":"24","author":[{"given":"Kristin","family":"Spik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Shurtleff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita K.","family":"McElroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary C.","family":"Guttieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie","family":"Schmaljohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25\u201326","key":"10.1016\/j.vaccine.2005.08.034_bib1","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/S0264-410X(03)00362-1","article-title":"Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus","volume":"21","author":"Riemenschneider","year":"2003","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3201\/eid0302.970202","article-title":"Hantaviruses: a global disease problem","volume":"3","author":"Schmaljohn","year":"1997","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2005.08.034_bib3","first-page":"171","article-title":"Vaccines against hantaviruses","volume":"256","author":"Hooper","year":"2001","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2005.08.034_bib4","article-title":"Bunyaviruses","volume":"vol. 1","author":"Gonzalez-Scarano","year":"1996"},{"issue":"9239","key":"10.1016\/j.vaccine.2005.08.034_bib5","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(05)74068-X","article-title":"More deaths from Rift Valley fever in Saudi Arabia and Yemen","volume":"356","author":"Ahmad","year":"2000","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.vaccine.2005.08.034_bib6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0749-0720(02)00029-4","article-title":"Rift valley fever","volume":"18","author":"Gerdes","year":"2002","journal-title":"Vet Clin North Am Food Anim Pract"},{"issue":"3","key":"10.1016\/j.vaccine.2005.08.034_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0264-410X(86)90007-1","article-title":"Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity trials","volume":"4","author":"Meadors","year":"1986","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2005.08.034_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2005.08.034_bib9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2005.08.034_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2005.08.034_bib11","first-page":"1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"issue":"10","key":"10.1016\/j.vaccine.2005.08.034_bib12","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2005.08.034_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","article-title":"Rift valley fever virus vaccine trial: study of neutralizing antibody response in humans","volume":"3","author":"Niklasson","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2005.08.034_bib14","first-page":"1043","article-title":"Flaviviruses","volume":"vol. 1","author":"Burke","year":"2001"},{"key":"10.1016\/j.vaccine.2005.08.034_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/jmv.1890060202","article-title":"Immunogenicity and reactogenicity of a highly purified vaccine against tidk-borne encephalitis","volume":"6","author":"Kunz","year":"1980","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/viro.1998.9586","article-title":"DNA vaccination with hantavirus M segment elicits neutralizing antibodies and protects against seoul virus infection","volume":"255","author":"Hooper","year":"1999","journal-title":"Virology"},{"issue":"18","key":"10.1016\/j.vaccine.2005.08.034_bib17","doi-asserted-by":"crossref","first-page":"8469","DOI":"10.1128\/JVI.75.18.8469-8477.2001","article-title":"DNA vaccination with the Hantaan virus M gene protects hamsters against three of four HFRS Hantaviruses and elicits a high-titer neutralizing antibody response in rhesus monkeys","volume":"75","author":"Hooper","year":"2001","journal-title":"J Virol"},{"issue":"18","key":"10.1016\/j.vaccine.2005.08.034_bib18","doi-asserted-by":"crossref","first-page":"9894","DOI":"10.1128\/JVI.77.18.9894-9905.2003","article-title":"Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine","volume":"77","author":"Custer","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2005.08.034_bib19","doi-asserted-by":"crossref","first-page":"9563","DOI":"10.1128\/JVI.71.12.9563-9569.1997","article-title":"Naked DNA vaccines expressing the prM and E genes of Russian Spring Summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge","volume":"71","author":"Schmaljohn","year":"1997","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.034_bib20","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/viro.1999.9918","article-title":"Evaluation of tick-borne encephalitis DNA vaccines in monkeys","volume":"263","author":"Schmaljohn","year":"1999","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.034_bib21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","article-title":"Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins","volume":"170","author":"Schmaljohn","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2005.08.034_bib22","series-title":"Vaccines 89","first-page":"371","article-title":"Mapping of protective determinants of Rift Valley fever virus using recombinant vaccinia viruses","author":"Dalrymple","year":"1989"},{"issue":"1\u20134","key":"10.1016\/j.vaccine.2005.08.034_bib23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF01316748","article-title":"Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies","volume":"121","author":"Besselaar","year":"1991","journal-title":"Arch Virol"},{"issue":"14","key":"10.1016\/j.vaccine.2005.08.034_bib24","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.1128\/JVI.76.14.7263-7275.2002","article-title":"Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus","volume":"76","author":"Sanchez","year":"2002","journal-title":"J Virol"},{"issue":"16","key":"10.1016\/j.vaccine.2005.08.034_bib25","doi-asserted-by":"crossref","first-page":"8640","DOI":"10.1128\/JVI.77.16.8640-8649.2003","article-title":"Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1","volume":"77","author":"Vincent","year":"2003","journal-title":"J Virol"},{"issue":"10","key":"10.1016\/j.vaccine.2005.08.034_bib26","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1128\/JVI.79.10.6152-6161.2005","article-title":"Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins","volume":"79","author":"Bertolotti-Ciarlet","year":"2005","journal-title":"J Virol"},{"issue":"9","key":"10.1016\/j.vaccine.2005.08.034_bib27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1089\/dna.1993.12.791","article-title":"Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization","volume":"12","author":"Eisenbraun","year":"1993","journal-title":"DNA Cell Biol"},{"issue":"9","key":"10.1016\/j.vaccine.2005.08.034_bib28","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1128\/JVI.76.9.4536-4546.2002","article-title":"Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines","volume":"76","author":"Arrington","year":"2002","journal-title":"J Virol"},{"issue":"15","key":"10.1016\/j.vaccine.2005.08.034_bib29","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/0264-410X(95)00069-D","article-title":"Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA","volume":"13","author":"Pertmer","year":"1995","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2005.08.034_bib30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1128\/JVI.62.3.826-833.1988","article-title":"Rift Valley fever virus M segment: use of recombinant vaccinia viruses to study Phlebovirus gene expression","volume":"62","author":"Kakach","year":"1988","journal-title":"J Virol"},{"issue":"4","key":"10.1016\/j.vaccine.2005.08.034_bib31","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1128\/JVI.64.4.1549-1555.1990","article-title":"Expression strategy of a phlebovirus: biogenesis of proteins from the Rift Valley fever virus M segment","volume":"64","author":"Suzich","year":"1990","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/0042-6822(89)90442-X","article-title":"Rift Valley fever virus M segment: phlebovirus expression strategy and protein glycosylation","volume":"170","author":"Kakach","year":"1989","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.034_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0042-6822(88)90174-2","article-title":"Rift Valley fever virus M segment: cellular localization of M segment-encoded proteins","volume":"166","author":"Wasmoen","year":"1988","journal-title":"Virology"},{"issue":"23","key":"10.1016\/j.vaccine.2005.08.034_bib34","doi-asserted-by":"crossref","first-page":"12200","DOI":"10.1128\/JVI.76.23.12200-12210.2002","article-title":"Characterization of the Golgi retention motif of Rift Valley fever virus G(N) glycoprotein","volume":"76","author":"Gerrard","year":"2002","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.4269\/ajtmh.1985.34.388","article-title":"Pathogenesis of Hantaan virus infection in suckling mice: clinical virologic, and serologic observations","volume":"34","author":"Kim","year":"1985","journal-title":"Am J Trop Med Hyg"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jmv.1890170203","article-title":"Hantaan virus infection in suckling mice: virologic and pathologic correlates","volume":"17","author":"McKee","year":"1985","journal-title":"J Med Virol"},{"issue":"19","key":"10.1016\/j.vaccine.2005.08.034_bib37","doi-asserted-by":"crossref","first-page":"9245","DOI":"10.1128\/JVI.74.19.9245-9255.2000","article-title":"Pathogenicity of Hantaan virus in newborn mice: genetic reassortant study demonstrating that a single amino acid change in glycoprotein G1 is related to virulence","volume":"74","author":"Ebihara","year":"2000","journal-title":"J Virol"},{"issue":"17","key":"10.1016\/j.vaccine.2005.08.034_bib38","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1128\/JVI.76.17.8890-8899.2002","article-title":"Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice","volume":"76","author":"Wichmann","year":"2002","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.vaccine.2005.08.034_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1006\/viro.1999.9961","article-title":"Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters","volume":"263","author":"Kamrud","year":"1999","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1006\/viro.1999.0096","article-title":"DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge","volume":"266","author":"Hooper","year":"2000","journal-title":"Virology"},{"issue":"7","key":"10.1016\/j.vaccine.2005.08.034_bib41","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.gene.6364125","article-title":"Effect on antibody and T-cell responses of mixing five GMP-produced DNA plasmids and administration with plasmid expressing GM-CSF","volume":"5","author":"Sedegah","year":"2004","journal-title":"Genes Immun"},{"issue":"23","key":"10.1016\/j.vaccine.2005.08.034_bib42","doi-asserted-by":"crossref","first-page":"12764","DOI":"10.1128\/JVI.77.23.12764-12772.2003","article-title":"Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines","volume":"77","author":"Kong","year":"2003","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2005.08.034_bib43","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1006\/bbrc.2001.4580","article-title":"Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens","volume":"282","author":"Musacchio","year":"2001","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0500842X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X0500842X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T06:41:24Z","timestamp":1706510484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X0500842X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":43,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0264410X0500842X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2005.08.034","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}